Agile Therapeutics, Inc. provided revenue guidance for the First quarter 2023. For the period, the Company expects net revenue is expected to be in the range of $3.8 to $4.0 million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3286 USD | -3.34% | -8.24% | -83.15% |
May. 15 | Agile Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 15 | Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q1 Revenue $5.7M | MT |
1st Jan change | Capi. | |
---|---|---|
-83.15% | 2.33M | |
+15.79% | 121B | |
+18.43% | 112B | |
+4.43% | 22.57B | |
-18.18% | 20.82B | |
-13.84% | 16.3B | |
-16.61% | 16.19B | |
-43.53% | 16.17B | |
+2.10% | 13.17B | |
+27.14% | 11.11B |
- Stock Market
- Equities
- AGRX Stock
- News Agile Therapeutics, Inc.
- Agile Therapeutics, Inc. Provides Revenue Guidance for the First Quarter 2023